Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Gyre Therapeutics (GYRE) Inventory (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Inventory for 2 consecutive years, with $6.3 million as the latest value for Q4 2024.

On a quarterly basis, Inventory rose 48.03% to $6.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $6.3 million, a 48.03% increase, with the full-year FY2024 number at $6.3 million, up 48.03% from a year prior.
Inventory was $6.3 million for Q4 2024 at Gyre Therapeutics, down from $6.4 million in the prior quarter.
In the past five years, Inventory ranged from a high of $6.4 million in Q3 2024 to a low of $4.3 million in Q4 2023.